The Recall Desk
ModerateFDA (Drugs)·D-1605-2020·Announced 2020-09-23

RLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations

RLC Labs Inc. is recalling Nature-Throid tablets because they were manufactured under conditions associated with subpotent products.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The source cites CGMP deviations and potential subpotency without reporting specific injuries or illnesses, fitting the Moderate criteria for low-risk contamination or voluntary precautionary recalls.

Plain-English summary

RLC Labs Inc. is voluntarily recalling Nature-Throid, Thyroid USP tablets. The product contains liothyronine (T3) and levothyroxine (T4) and is available in 30, 60, 90, 100, and 1,000-count bottles. The recall covers all lots with expiration dates between October 2020 and July 2023.

The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The source text states that the affected products were manufactured under the same conditions as those found to be subpotent. This suggests a potential risk that the tablets may not contain the full labeled amount of active ingredients.

The product was distributed nationwide in the United States. Consumers and healthcare providers should stop using the recalled products and contact their healthcare provider or pharmacist for guidance on alternative treatment options.

The recalled product

Product
Nature-Throid, Thyroid USP [liothyronine (T3) 27 mcg and levothyroxine (T4) 114 mcg], 3 Grain (195 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3312-4; b) 60-count bottles, NDC 64727-3312-5; c) 90-count bottles, NDC 64727-3312-6; d) 100-count bottles, NDC 64727-3312-1
Manufacturer
RLC Labs Inc.
Category
Drug — Thyroid Hormone
Hazard

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots with expiry between 10/2020-07/2023

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 24 recalled by RLC Labs Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 24 products in this recall →

Related recalls

Same manufacturer · RLC Labs Inc.

See all →

Same hazard · subpotency

See all →